Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine dosing for ESP block
NCT03961048Phase 4Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2019
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of ropivacaine in postoperative pain, chest pain, sponsored by Virginia Commonwealth University. Planned start Jul 2019; status: withdrawn.
02
Drugs
ropivacaine
03
Conditions
postoperative painchest pain
Beyond the preview
Go deeper on NCT03961048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03961048.